quick facts

Problem: most computational drug discover methods used by the pharmaceutical industry focus on already existing or commercially available chemical libraries and have failed to generate high-quality leads agains difficult to drug targets.

Novel Approach Technology, SCULPT. Fragment-based computational approach, enhanced with multiple Artificial Intelligence tools for new drug design of pre-optimized target specific libraries of compounds with drug-like properties.

Strong and diverse pipeline with 8 programs, 3 of them partnered, in different preclinical stages for the treatment of cancer, infectious diseases ad DMD. The most advanced program in Leukemia will reach pre-IND in 2019.

Successfully raised $5 million across various partnerships and through private investors.

Collaborations with former management of Pharmacyclics, Novartis, J&J, P&G and Insilico Medicine to advance new drug candidates toward IND.

menu
Contact

BioLabs New York
180 Varick Street
New York, NY 10014

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

© 2019 A2A Pharma. All rights reserved